Design of Lentivirus Based Vaccines for Cancer

  • Check with publisher
  • Published date: January 28, 2019
    • Shirley, New York, United States

Lentiviral vectors (LVs) have been identified as potentially more effective and safer alternative delivery vehicles. LVs are now in use in clinical trials for many different types of inherited and acquired disorders, including cancer. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for lentivirus-based vaccines. We guarantee the finest results for our customers all over the world.

Lentivirus
Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in the human and other mammalian species. Lentiviruses can integrate a significant amount of viral RNA into the DNA of the host cell and can efficiently infect nondividing cells, so they are one of the most efficient methods of gene delivery. Lentiviruses can become endogenous (ERV), integrating their genome into the host germline genome, so that the virus is henceforth inherited by the host's descendants.

Result 0 votes
Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • 5th Annual Advances in Immuno-Oncology Congress

    5th Annual Advances in Immuno-Oncology Congress

    Life Sciences London (London) November 12, 2019 Check with publisher

    Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions developing immuno-oncology therapies and tools. Over 60 presentations, case studies and p...

  • 7th Annual Peptides & Oligonucleotides Congress

    7th Annual Peptides & Oligonucleotides Congress

    Life Sciences London (United Kingdom) November 6, 2019 Check with publisher

    Over 150 attendees working in peptides and oligonucleotides, representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions. Over 40 case studies, presentations and panel discussions foc...

  • Recombinant Huaiyangshan Virus Nucleocapsid Protein (aa 1-252) [His]

    Recombinant Huaiyangshan Virus Nucleocapsid Protein (aa 1-252) [His]

    Life Sciences Shirley (New York) October 28, 2019 Check with publisher

    Huaiyangshan virus (HYSV) is a novel tick-borne bunyavirus. It causes haemorrhagic fever-like disease and has recently been reported in China. https://www.creative-biolabs.com/vaccine/recombinant-huaiyangshan-virus-nucleocapsid-protein-aa-1-252-his-6...